MistGo® – the future of eye treatment

click on animation for sound

MistGo® – a superior alternative to conventional eye drops

  • Eye Drops

    Eye Drops



  • Microdosing ability & precision



    Optimal dose. Precise instillation. Every time.

  • Ease of use and comfort for patient



    Easy and comfortable to use

  • Risk of cross contamination



    Minimizes risks of cross contamination or eye trauma

  • Preservative-free drug compatibility



    Compatible with preservative-free eye medications

Poor installation techniques jeopardizes compliance to treatment

Of the routes to administer drugs to the eye, the topical route is the most used. Unfortunately, the design of the eye drop bottle leads many patients to administer their medication incorrectly.

Studies prove that among glaucoma patients, the proportion of patients using improper technique ranges from 34% to 92%. 7-44% miss the eye completely and 18-80% contaminate the tip of the bottle by contacting the eye or surrounding tissue.



1: Atey TM et al, “The impact of adherence and instillation proficiency of topical glaucoma medications on intraocular pressure”. J Ophthalmoly, 2017, Vol 2017, Article 1683430; Schein OD et al, “Microbial contamination of in-use ocular medications”. Arch Ophthalmol, 1992, Vol 110, pp 82–85; Sleath B, Blalock S, Covert D et al, “The relationship between glaucoma medication adherence, eye drop technique, and visual field defect severity”. Ophthalmology, 2011,Vol 118, pp 2398–2402; Gupta R et al, “Evaluating eye drop instillation technique in glaucoma patients”. J Glaucoma, 2012,Vol 21, pp 189–192; Tatham AJ et al, “Eye drop instillation technique in patients with glaucoma”. Eye, 2013,Vol 27 pp 1293–1298; Konstas AG et al, “Compliance and viewpoint of glaucoma patients in Greece”. Eye, 2000, Vol 14,pp 752–756; Kholdebarin R et al, “Multicenter study of compliance and drop administration in glaucoma”. Can J Ophthalmology, 2008,Vol 43, pp 454–461; Stone JL et al, “An objective evaluation of eyedrop instillation in patients with glaucoma”. Arch Ophthalmol, 2009, Vol 127,pp 732–736; Mehari T, Giorgis AT, Shibeshi W, “Appropriateness and determinants of proper administration technique of ocular hypotensive agents among glaucoma patients in Menelik II referral hospital, Ethiopia”. J Clin Exp Ophthalmol, 2016, Vol 7(3); Hennessy AL, Katz J, Covert D et al, “A video study of drop instillation in both glaucoma and retina patients with visual impairment”. Am J Ophthalmol, 2011, Vol 152,pp 982–998; Schwartz GF, Hollander DA, Williams JM, “Evaluation of eye drop administration technique in patients with glaucoma or ocular hypertension”. Curr Med Res Opin, 2013, Vol 29, pp 1515–1522: Brown MM, Brown GC, Spaeth GL, “Improper topical self-administration of ocular medication among patients with glaucoma”. Can J Ophthalmol, 1984, Vol 19, pp 2–5; Hosoda M et al, “Do glaucoma patients use eye drops correctly?” J Glaucoma, 1995, Vol 4, pp 202–206; Tsai T, Robin AL, Smith JP 3rd,“An evaluation of how glaucoma patients use topical medications: a pilot study”. Trans Am Ophthalmol Soc, 2007, Vol 105, pp 29–33.

MistGo® is a user-friendly alternative increasing compliance

MistGo® is an innovative alternative to the conventional eye drop bottle, designed to help patients administer their eye medication in a more precise and user-friendly way.

The better user experience translates into higher patient compliance, healthier eyes and higher quality of life for patients.

It’s delightfully easy to use.
You can’t possibly do it wrong.
It solves all the hassles with eye drops.

Quote from user study 2023.

MistGo® is designed to be omni-directional
It can be used horizontally

Studies show that microdosing is as safe and efficacious as normal eye drops

Medicating with an eye dropper result in a drop containing 30-50 μl which greatly exceeds the physiologic 6-8 μL ocular tear film capacity.

A part of the delivered solution is washed out of the eye, but up to 80% of the dose enters the systemic circulation via transport into surface blood vessels or passage through the nasal lacrimal duct and into the digestive system, leading to an increased risk of systemic adverse events.

Any excess solution remaining in the eye can lead to local adverse events, incl. hypersensitivity reactions to the drug or excipients.

From a biopharmaceutical and economic point of view, the ideal would be to instill smaller volumes of eye medication as they can achieve a maximal tear film concentration with far less systemic absorption.

1: Washington N, Washington C, Wilson CG, “Ocular drug delivery”. Physiological Pharmaceutics: Barriers to Drug Absorption, 2nd edition, CRC Press, 2001, pp 249–270.; Mishima S et al, “Determination of tear volume and tear flow”. Invest Ophthalmol, 1966, Vol 5(3), pp 264–276.; Scherz W, Doane MG, Dohlman CH, “Tear volume in normal eyes and keratoconjunctivitis sicca”. Albrecht Von Graefes Arch Klin Exp Ophthalmol, 1974, Vol 192(2), pp 141–150.; Quiroz-Mercado H, Ivri E, Gonzalez-Salinas R, Kourtis IC, Gilbert J, Pérez-Vázquez JF, Blumenkranz M, Jiménez-Román J, Marcellino G. Clinical Evaluation of a Novel Electromechanical Topical Ocular Drug Delivery System: Two Phase 1 Proof of Concept Studies. Clin Ophthalmol. 2020 Jan 20;14 pp 139-147; Van Santvliet L, Ludwig A, “Determinants of eye drop size”.Surv Ophthalmol, 2004, Vol 49(2), pp 197-213.; Brown RH, Hotchkiss ML, Davis EB, “Creating Smaller Eyedrops by Reducing Eyedropper Tip Dimensions”. Am JOphthalmol, 1985, Vol 99(4), pp 460-464.; Collins JF, Dartt DA, Dana R. Mist delivery of eye medication to the anterior segment. Am J Ophthalmol. 2007 Jul;144(1):137-9

MistGo® is designed to microdose

MistGo® features a high-precision micropump that consistently meters a dose of 6 μL, eliminating or reducing the excess liquid to an absolute minimum. This helps to reduce or completely eliminate the risk of skin irritation, systemic circulation and adverse events.

The internal geometry of the nozzle is designed to vaporise the drug into a fine mist with a broad impact pattern, coating the entire cornea for optimal absorption (~10-12 mm diameter).






MistGo® misting salt water

Preservative-free eye medication requires sterility in delivery system

Eye drops delivered in a multidose container must maintain sterility of the contents throughout the use period, as microbial keratitis is a risk for users of topical ophthalmic solutions upon accidental contamination of the product.

Antimicrobial activity is often achieved through the addition of preservatives,  the most frequently used benzalkonium chloride (BAK), which due to toxicity have deleterious effects on the ocular surface.

Removal of the preservative eliminates preservative-induced complications.

A preservative-free eye medication must be dispensed in a delivery system designed to keep the liquid formulation sterile throughout the treatment period.

MistGo® – can be used for medication both with and without preservatives

MistGo® is airtight and designed to maintain sterility in the following way:

  • Integrates a collapsible multilayer cartridge obviating air ventilation. No backflow of (contaminated) air requiring filtering.
  • The liquid is sealed off from the environment using nonpermeable materials. Several barriers are established to separate the liquid from the environment.
  • The system enables pressurized air to both create the mist and completely clean the outlet nozzle chamber after dispensing. The liquid column is broken, and no liquid is left for later microbiocidal contamination.
  • An eye interface protects the nozzle from contamination caused by user contact, and a cap helps protect the dosing chamber during storage between use.

MistGo® has a large performance window and is customizable to many drugs – including the sticky ones

Parameters in MistGo® can be customized to suit the needs of individual drugs including those with high viscosity enabling the delivery system to perform optimally for liquids for a variety of both Rx (prescription) and OTC (over the counter) medicines

  • Micro-dosing: a high-precision pump consistently meters a dose of 6 μL, dispensing no excess liquid to irritate the skin or enter systemic circulation.
  • Delivery time: the dose is fully delivered before the eye can blink
  • Gentle: the internal geometry of the nozzle is optimized to vaporize the liquid into a fine mist of micro droplets, which feels comfortable and soothing in the eye compared to a single dense drop
  • Precision: the entire mist is delivered precisely within the target area: the cornea (11mm diameter when the eye is fully open)